Highest-materiality recent filing
AEON Biopharma posts corporate presentation targeting $3.5B neurotoxin market
Corporate presentation made available on IR website, dated May 2026.
AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%
FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.
AEON Biopharma gets second NYSE American delisting notice over $55M equity deficit
March 31, 2026 notice: not compliant with Section 1003(a)(ii) requiring ≥$4M stockholders' equity.
AEON Biopharma reports positive biosimilarity data for ABP-450, raises $6M PIPE, reduces debt 90%
Initial analytical results confirm 100% amino-acid sequence match to BOTOX and highly similar functional characteristics.
AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares
John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.
AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA
Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.
AEON Biopharma issues corporate presentation with no new material facts
Presentation dated January 2026 made available on IR website (Item 7.01).
Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.
AEON Biopharma posts corporate presentation with biosimilar pipeline update
Presentation dated December 2025 highlights fresh data and new capital for full-label biosimilar approval.
AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction
ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.
AEON Biopharma raises $6M private placement, plans Daewoong note exchange for ~23M shares
First closing of private placement expected week of Nov 17, 2025: 1,964,905 shares/pre-funded warrants at $0.9116 per share.
AEON Biopharma makes corporate presentation available; limited specifics disclosed
Presentation references $3B+ U.S. neurotoxin therapeutic market via biosimilarity approach.
AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones
Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.
AEON Biopharma elects Fischer and Carter as Class II directors; ratifies KPMG
Jost Fischer and Eric Carter elected as Class II directors for three-year terms ending 2028.
AEON Biopharma presents corporate update at Aegis Capital Conference, focusing on PrabotulinumtoxinA
Presentation highlights PrabotulinumtoxinA as a therapeutic botulinum toxin product candidate.
AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash
Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.
NYSE American accepts AEON's compliance plan; delisting risk deferred to Aug 2026
NYSE American accepted AEON's compliance plan on April 22, 2025, granting until August 3, 2026 to meet listing standards under Sections 1003(a)(i)-(iii).
AEON Biopharma appoints Robert Bancroft as CEO effective April 29; Jost Fisher remains chairman
Bancroft appointed PEO, President, CEO and Class I director effective April 29, 2025.
AEON Biopharma appoints Jost Fischer Interim CEO and Jennifer Sy as principal financial officer
On April 3, 2025, Board formally appointed Jost Fischer as Interim President, CEO and principal executive officer, effective April 4, 2025.
AEON CEO Marc Forth resigns; Chairman Jost Fischer named interim CEO
Marc Forth steps down as President and CEO effective April 4, 2025, to pursue another opportunity.
AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding
Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.
AEON Biopharma posts corporate presentation; details limited
Presentation made available on IR website on March 10, 2025.
AEON Biopharma approves 1-for-72 reverse stock split to maintain NYSE American listing
Reverse split ratio of 1-for-72; effective 12:01 AM ET on February 26, 2025.
AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M
Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.
AEON Biopharma closes $20M public offering; net proceeds ~$18.3M
Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).
AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025
Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.
Aeon Biopharma reduces shareholder quorum requirement to 33.34%
Quorum for shareholder meetings changed from a majority to 33.34% of outstanding voting power.
AEON Biopharma Q3 2024: FDA aligned on biosimilar path for ABP-450, but capital constraints persist
Held Biosimilar Initial Advisory meeting with FDA in Q3; aligned on 351(k) pathway using BOTOX as reference.
AEON Biopharma posts new corporate presentation highlighting prabotulinumtoxinA biosimilar
Corporate presentation posted on IR site on October 7, 2024, used for investor meetings.
AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024
ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.
AEON Biopharma posts new corporate presentation; no financial updates disclosed
New corporate presentation posted on August 6, 2024, highlighting PrabotulinumtoxinA as a biosimilar candidate.
ABP-450 will pursue 351(k) biosimilar pathway using AbbVie's BOTOX as reference product.
Robert Palmisano and Shelley Thunen elected as Class I directors for three-year terms ending 2027.
Phase 2 double-blind migraine study (episodic and chronic cohorts) discontinued; chronic cohort failed primary and secondary endpoints.
AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints
Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.
AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint
Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.
AEON Biopharma restates 2023 financials; non-cash error adds $348M loss; going concern doubt
Board concludes Q3 2023 and FY 2023 financials unreliable due to IPR&D write-off misclassification.
Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.
On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.
On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.
On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.
The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.
On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.
On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.
On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.
On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.
Max materiality 0.85 · Median 0.65 · Most common event other_material